Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the efficacy of lithium carbonate in the treatment of neuropathic pain of patients with spinal cord injury.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury

NCT01748695

Neuropathic Pain Due to Spinal Cord Injury

COMPLETED PHASE2

Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP). Preliminary Study.

NCT02705950

Neuropathic Pain

COMPLETED NA

Impact of Peripheral Afferent Input on Central Neuropathic Pain

NCT05646810

Spinal Cord Injuries Spinal Cord Diseases Syringomyelia

UNKNOWN NA

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

NCT05581199

Chronic Inflammatory Demyelinating Polyneuropathy

ACTIVE_NOT_RECRUITING PHASE2

Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic

NCT03942848

Severe Refractory Neuropathic Pain Spinal Cord Lesions

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, placebo-controlled, double-blinded trial. Sixty spinal cord injured subjects with neuropathic pain will be randomized into two groups. The subject in the Treatment Group will receive lithium carbonate tablet, while the Control Group will receive placebo tablet. Neither the subjects nor the physicians know which group the subjects are allocated.

Each subject will receive 6 weeks of oral lithium carbonate or placebo. In the Treatment Group, the dose will be adjusted according to the serum lithium level. While in the Control Group, the dose will be adjusted based on the dummy serum level report.

The outcome will be assessed during visits at 1 week, 2 weeks, 6 weeks and 12 weeks, and a phone call follow-up at 24 weeks from the start of the medication. The primary outcome measure is the severity level of pain. The efficacy and safety will be analyzed by comparing the results of the Treatment Group with those of the Control Group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathic Pain Neuralgia Spinal Cord Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lithium treatment group

Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.

Group Type EXPERIMENTAL

Lithium Carbonate

Intervention Type DRUG

250 mg/tablet, 6 weeks course of oral administration

Control group

The dose of the placebo will be adjusted according to the dummy serum level report.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo tablet, 6 week course of oral administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lithium Carbonate

250 mg/tablet, 6 weeks course of oral administration

Intervention Type DRUG

Placebo

placebo tablet, 6 week course of oral administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 - 65;
* Diagnosis of traumatic spinal cord injury;
* Clinically diagnosed neuropathic pain;
* Pain severity is at least 4 on a 11-point numeric rating scale at screening;
* Pain present regularly for at least 6 weeks before enrollment;
* Able to understand instructions and provide reliable pain assessments;
* Subjects who are voluntarily signed and dated an Ethics Committee approved informed consent form;

Exclusion Criteria

* Significant renal, cardiovascular, hepatic, infectious or psychiatric disease;
* Significant brain injury with neurological deficits;
* Debilitation or dehydration;
* Addison's disease;
* Recent (within 1 week) or current use of anti-diuretics or other drugs that interacts with lithium, such as tricyclic antidepressants, nonsteroidal antiinflammatory drug and tetracyclines;
* A history of substance or alcohol abuse within past 1 year;
* A need for elective surgery involving preoperative or postoperative analgesics or anesthetics during the study period;
* Current pregnant or breast feeding, or female who has childbearing potential but is not willing to use an approved method of birth control;
* Participation in any drug study in the last three months;
* History of oral lithium intake for any reason; or
* any criteria, which in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No